Elson Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 17 Year, 1 Month
- Last Filing with ROC 31 Mar 2016
- Open Charges ₹ 6.13 M
- Revenue Growth -53.82%
- Profit Growth -83.37%
- Ebitda 23.01%
- Net Worth 0.09%
- Total Assets -13.17%
About Elson Pharma
Elson Pharma Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 January 2008 and has a history of 17 years and one month. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2016. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹6.13 M.
Sandhya Singla and Taru Bharadwaaj serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232DL2008PTC172385
-
Company No.
172385
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Jan 2008
-
Date of AGM
30 Sep 2016
-
Date of Balance Sheet
31 Mar 2016
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Elson Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandhya Singla
|
Director | 08-Jan-2008 | Current |
|
Taru Bharadwaaj
|
Director | 09-Jan-2009 | Current |
Financial Performance of Elson Pharma.
Elson Pharma Private Limited, for the financial year ended 2016, experienced significant reduction in revenue, with a 53.82% decrease. The company also saw a substantial fall in profitability, with a 83.37% decrease in profit. The company's net worth moved up by a moderate rise of 0.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elson Pharma?
In 2016, Elson Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹6.13 M
₹0
Charges Breakdown by Lending Institutions
- Syndicate Bank : 0.61 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Nov 2012 | Syndicate Bank | ₹0.48 M | Open |
| 08 Nov 2012 | Syndicate Bank | ₹0.65 M | Open |
| 05 Jul 2012 | Syndicate Bank | ₹5.00 M | Open |
How Many Employees Work at Elson Pharma?
Unlock and access historical data on people associated with Elson Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elson Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elson Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
